Adenoviral (Ad5) therapeutic cancer vaccine encoding CEA, MUC1, and brachyury to prime and expand antigen-specific CD4+/CD8+ T cells.
Non-replicating adenoviral (Ad5) therapeutic cancer vaccine encoding CEA, MUC1, and brachyury. Transduces antigen-presenting cells to express these tumor antigens, leading to MHC I/II presentation and priming/expansion of antigen-specific CD8+ and CD4+ T cells that recognize and kill antigen-expressing tumor cells.
YES
INDIRECT
The Ad5 vaccine transduces APCs to present brachyury peptides, priming brachyury-specific CD8+ T cells that recognize peptide–MHC I on tumor cells and kill them via perforin/granzyme (and Fas/FasL) cytotoxicity.
Subcutaneous anti-CD20 monoclonal antibody that depletes CD20+ B cells via complement-dependent cytotoxicity and ADCC.
Fully human anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes CD20+ B lymphocytes via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), thereby reducing pathogenic B-cell activity.
YES
DIRECT
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated effector killing (ADCC/ADCP), leading to lysis of CD20+ cells.
An antibody–drug conjugate (human IgG1) targeting B7-H3 (CD276); upon binding and internalization, a cleavable linker releases a duocarmycin DNA-alkylating payload that induces minor-groove alkylation and tumor cell death; the IgG1 backbone may contribute Fc-mediated cytotoxicity and a bystander effect.
Human IgG1 antibody–drug conjugate targeting B7-H3 (CD276). Upon antigen binding and internalization, a cleavable linker releases a duocarmycin payload that alkylates DNA in the minor groove, inducing tumor cell death; the IgG1 Fc may contribute ADCC/CDC and a bystander effect.
YES
DIRECT
ADC binds B7-H3, is internalized, and releases a duocarmycin payload that alkylates DNA, killing the cell; IgG1 Fc can also mediate ADCC/CDC (plus bystander effect).
An antibody–drug conjugate (human IgG1) targeting B7-H3 (CD276); upon binding and internalization, a cleavable linker releases a duocarmycin DNA-alkylating payload that induces minor-groove alkylation and tumor cell death; the IgG1 backbone may contribute Fc-mediated cytotoxicity and a bystander effect.
Human IgG1 antibody–drug conjugate targeting B7-H3 (CD276). Upon antigen binding and internalization, a cleavable linker releases a duocarmycin payload that alkylates DNA in the minor groove, inducing tumor cell death; the IgG1 Fc may contribute ADCC/CDC and a bystander effect.
YES
INDIRECT
After the ADC binds B7‑H3 and is internalized, its duocarmycin payload is released and alkylates the DNA minor groove, causing DNA damage and tumor cell death; Fc effector/bystander effects may contribute.
An anti-CD38 antibody–drug conjugate (anti-CD38–Duostatin 5.2) that binds CD38 on clonal plasma cells, is internalized, and releases the Duostatin 5.2 cytotoxic payload to induce selective plasma-cell killing and reduce pathogenic light-chain production in systemic AL amyloidosis.
CD38-targeting antibody–drug conjugate that binds CD38 on plasma cells, is internalized, and releases an MMAF (Duostatin 5.2) cytotoxic payload to inhibit tubulin polymerization, causing G2/M arrest and apoptosis of CD38+ cells, thereby reducing pathogenic light-chain production in AL amyloidosis.
YES
DIRECT
The anti-CD38 ADC binds CD38+ cells, is internalized, and releases an MMAF payload that inhibits tubulin polymerization, causing G2/M arrest and apoptosis.